Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy.


Dendritic cell (DC)-based immunotherapy has recently demonstrated a great potential for clinical applications; however, additional progress in the methods of tumor-specific antigen delivery to DCs is necessary for the further development of anti-tumor vaccines. To this end, a capsid-optimized adeno-associated virus serotype 6 (AAV6-T492V+S663V) vector was… (More)
DOI: 10.1038/icb.2013.74


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.